The cryptophycin drug-payload and cryptophycin-ADC (CpADC) averaged an 80% cancer cell kill rate across the tested cancer cell lines and significantly outperformed MMAE. In a broad range of ...

The FDA granted the ADC an accelerated approval on the basis ... which using a topoisomerase 1 inhibitor instead of an MMAE cytotoxin as its therapeutic payload. Telisotuzumab adizutecan is ...

12.299. Image Credit: Sino Biological Inc. Immobilized MMAE-ADC at 1 μg/mL (100 μL/well) can bind the Anti-MMAE Antibody, the EC₅₀ of Anti-MMAE is 50 -1000 ng/mL. The naked antibody (without ...

EBC-129 demonstrates early activity and manageable safety in patients with heavily pretreated pancreatic cancer, supporting ...

PRO1107 is an ADC comprised of a Protein Tyrosine Kinase 7 (PTK7)-targeted antibody conjugated to ProfoundBio’s novel, proprietary hydrophilic MMAE-based linker-drug, LD343, at a homogeneous DAR ...

Additionally, IPH4502 shows efficacy in models resistant to MMAE-ADC. These results support its potential for development beyond UC and in cancer patients treated with MMAE-based ADCs. Innate ...

ADC construct designated – SON-5010 showed similar activities as compared with Kadcyla® and also trastuzumab-MMAE, in a preclinical study Company’s ADC Platform offers the potential for novel ...

One area that ADC makers are still grappling with is how stable to make the linker. Sandall says that with the MMAE payload, making the linker more stable makes the ADC more toxic. “So far ...

BOSTON, April 25, 2025 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat ...

In that poster, we used [a] MMAE payload.” At the Piper Sandler event, Ferra declined to answer an analyst’s question about whether the ADC uses site-specific conjugation. The deal clears up ...